| Literature DB >> 28365253 |
Yoshifumi Kimizuka1, John J Callahan2, Zilong Huang3, Kaitlyn Morse1, Wataru Katagiri4, Ayako Shigeta1, Roderick Bronson5, Shu Takeuchi1, Yusuke Shimaoka1, Megan P K Chan1, Yang Zeng1, Binghao Li1, Huabiao Chen1, Rhea Y Y Tan1, Conor Dwyer1, Tyler Mulley2, Pierre Leblanc1, Calum Goudie1, Jeffrey Gelfand1, Kosuke Tsukada4, Timothy Brauns1, Mark C Poznansky1, David Bean6, Satoshi Kashiwagi7.
Abstract
A brief exposure of skin to a low-power, non-tissue damaging laser light has been demonstrated to augment immune responses to intradermal vaccination. Both preclinical and clinical studies show that this approach is simple, effective, safe and well tolerated compared to standard chemical or biological adjuvants. Until now, these laser exposures have been performed using a diode-pumped solid-state laser (DPSSL) devices, which are expensive and require labor-intensive maintenance and special training. Development of an inexpensive, easy-to-use and small device would form an important step in translating this technology toward clinical application. Here we report that we have established a handheld, near-infrared (NIR) laser device using semiconductor diodes emitting either 1061, 1258, or 1301nm light that costs less than $4000, and that this device replicates the adjuvant effect of a DPSSL system in a mouse model of influenza vaccination. Our results also indicate that a broader range of NIR laser wavelengths possess the ability to enhance vaccine immune responses, allowing engineering options for the device design. This small, low-cost device establishes the feasibility of using a laser adjuvant approach for mass-vaccination programs in a clinical setting, opens the door for broader testing of this technology with a variety of vaccines and forms the foundation for development of devices ready for use in the clinic.Entities:
Keywords: Adjuvant; Handheld; Laser; Near-infrared; Semiconductor laser diode; Vaccine
Mesh:
Substances:
Year: 2017 PMID: 28365253 PMCID: PMC5576344 DOI: 10.1016/j.vaccine.2017.03.036
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641